Compare · IGC vs NVO
IGC vs NVO
Side-by-side comparison of IGC Pharma Inc. (IGC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IGC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 8536.9x IGC ($25.3M).
- Over the past year, IGC is down 27.7% and NVO is down 29.3% - IGC leads by 1.6 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for IGC).
- Company
- IGC Pharma Inc.
- Novo Nordisk A/S
- Price
- $0.27+2.01%
- $48.78+1.22%
- Market cap
- $25.3M
- $215.95B
- 1M return
- +0.94%
- +2.89%
- 1Y return
- -27.65%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 4
- 4
- Recent ratings
- 0
- 25
IGC Pharma Inc.
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. The company operates through two segments, Infrastructure Business, and Life Sciences. It buys and sells infrastructure commodities, such as steel, wooden doors, marble, and tiles; rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. The company also develops cannabinoid-based products and therapies, such as Hyalolex for the treatment of patients from anxiety, agitation, dementia, depression, and sleep disorder diseases; hemp-based CBD infused products under the Holief brand name; premium hemp-based CBD infused organic topical and spa line of products under the Herbo brand name; and premium hemp-based CBD infused seltzer under the Sunday Seltzer brand. In addition, it offers offer trading, distillation, tolling, and white labeling services under the Holi Hemp brand; and hemp crude extracts, hemp isolates, and hemp distillates. The company operates in the United States, India, Colombia, and Hong Kong. India Globalization Capital, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IGC
- IGC Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
- IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
- IGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- CEO Mukunda Ram was granted 2,226,475 shares, increasing direct ownership by 48% to 6,875,563 units (SEC Form 4)
- PFO Grimaldi Claudia was granted 2,048,378 shares, increasing direct ownership by 149% to 3,421,092 units (SEC Form 4)
- IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
- IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
- Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
- IGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S